Literature DB >> 12410702

Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment.

P Foulc1, V Evrard, S Dalac, B Guillot, M Delaunay, J-L Verret, B Dréno.   

Abstract

BACKGROUND: Mechlorethamine is frequently used in the treatment of cutaneous lymphoma, but its application is limited in 30-80% of cases because of cutaneous intolerance. Reducing the concentration to avoid this side-effect has been only modestly successful.
OBJECTIVES: To investigate whether a shorter application period could reduce the frequency of intolerance.
METHODS: In an open prospective study in 39 patients with cutaneous T-cell lymphoma or parapsoriasis, mechlorethamine was applied according to the usual practices of the participating physicians (number of weekly applications, treatment confined to lesions or performed over the entire body) and then washed off after 1 h in all cases.
RESULTS: Cutaneous intolerance was observed in 19 of 39 patients (49%). Six of these patients showed allergic contact dermatitis to mechlorethamine after a mean period of 9.3 weeks, while the other 13 developed irritant contact dermatitis after a longer period. Cutaneous intolerance did not differ significantly according to the number of applications per week or the extent of body area treated. The therapeutic response rate was 69%, and no difference in therapeutic efficacy was noted between daily and intermittent applications.
CONCLUSIONS: Comparison with published studies showed no significant difference in the number of cases of cutaneous intolerance after short-term application, although their occurrence was delayed. Therapeutic response was decreased appreciably by short-term application as compared with results in the literature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410702     DOI: 10.1046/j.1365-2133.2002.04802.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Impaired healing of nitrogen mustard wounds in CXCR2 null mice.

Authors:  Snjezana Milatovic; Lillian B Nanney; Yingchun Yu; John R White; Ann Richmond
Journal:  Wound Repair Regen       Date:  2003 May-Jun       Impact factor: 3.617

Review 2.  Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review.

Authors:  Ebba Wennberg; Phillip Q Richards; Paul A Bain; Victor Huang; Sydney D Sullivan; Emanual M Maverakis; Gabriel E Molina; Peggy A Wu
Journal:  JAAD Int       Date:  2021-03-11

Review 3.  Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience.

Authors:  Larisa J Geskin; Martine Bagot; Emmilia Hodak; Ellen J Kim
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-21

Review 4.  Therapy for mycosis fungoides.

Authors:  Jeanette Lundin; Anders Osterborg
Journal:  Curr Treat Options Oncol       Date:  2004-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.